Severe/Resistant Hypercholesterolemia: New Agents Redefining Clinical Practice

Since hypercholesterolemia is a major driver of ASCVD, lipid-lowering therapies (mainly in combination with statins) are the primary approach to lower low-density lipoprotein cholesterol (LDL-C) and reduce CVD risk. Unfortunately, intensive statin therapy lowers CVD risk by only ~50%, leaving many patients at excessively high residual CVD risk. Recently approved PCSK9 inhibitors have been shown to produce robust LDL-C reduction (by ~60%) when co-administered with statins.

Severe/Resistant Hypercholesterolemia: New Agents Redefining Clinical Practice will help clinicians develop a refined understanding of residual CVD risk in hypercholesterolemic patients and allow them to adjust prescribing behavior to reduce risk as much as possible.

EDUCATIONAL OBJECTIVES - At the conclusion of this activity, participants should be able to demonstrate the ability to:

- Evaluate the relationship between residual hypercholesterolemia and residual CVD risk in high-risk patients
- Define CVD risk elements to guide prescribing behavior
- Differentiate the clinical properties of new and emerging pharmacologic approaches to reduce LDL-C and lower CVD risk
- Analyze the potential strengths and weaknesses of new approaches to reduce CVD risk in combination with statins
- Implement use of newer LDL-C lowering agents in combination with statins